Kamada (KMDA) Projected to Post Earnings on Wednesday

Kamada (NASDAQ:KMDA) will likely be releasing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Kamada to post earnings of $0.09 per share and revenue of $145.0670 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 7:00 AM ET.

Kamada Price Performance

NASDAQ KMDA opened at $9.20 on Wednesday. Kamada has a 1-year low of $5.54 and a 1-year high of $9.27. The business has a 50 day simple moving average of $7.97 and a two-hundred day simple moving average of $7.31. The stock has a market capitalization of $529.09 million, a PE ratio of 25.56, a P/E/G ratio of 0.76 and a beta of 0.94.

Institutional Investors Weigh In On Kamada

Several hedge funds and other institutional investors have recently modified their holdings of the business. NewEdge Advisors LLC lifted its stake in shares of Kamada by 9.2% during the 4th quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 4,870 shares during the last quarter. XTX Topco Ltd purchased a new stake in Kamada in the fourth quarter worth $103,000. Quadrature Capital Ltd lifted its position in shares of Kamada by 53.5% during the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 7,627 shares during the last quarter. Man Group plc boosted its stake in shares of Kamada by 19.9% during the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,684 shares during the period. Finally, SIH Partners LLLP bought a new position in shares of Kamada in the fourth quarter worth about $134,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on KMDA shares. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. HC Wainwright lifted their price objective on shares of Kamada from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen raised Kamada from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Finally, Benchmark restated a “buy” rating on shares of Kamada in a research report on Thursday, January 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.